

REGISTERED NUMBER: 12376521 (England and Wales)

UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

FOR

A-TEK PHARMA LTD

**CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025**

	Page
Company Information	1
Balance Sheet	2
Notes to the Financial Statements	3
Chartered Certified Accountants' Report	6

A-TEK PHARMA LTD
COMPANY INFORMATION
FOR THE YEAR ENDED 31 DECEMBER 2025

DIRECTOR: E Singh Chuhan

REGISTERED OFFICE: 138 Lower Ashley Road
Easton
Bristol
BS5 0YL

REGISTERED NUMBER: 12376521 (England and Wales)

ACCOUNTANTS: MDH
Chartered Certified Accountants
21 Stafford Road
Croydon
Surrey
CR0 4NG

BALANCE SHEET
31 DECEMBER 2025

	Notes	31/12/25 £	£	31/12/24 £	£
FIXED ASSETS					
Tangible assets	4		5,165		6,857
CURRENT ASSETS					
Stocks		-		5,200	
Debtors	5	765		38,046	
Cash at bank		<u>243,756</u>		<u>248,555</u>	
		244,521		291,801	
CREDITORS					
Amounts falling due within one year	6	<u>319,052</u>		<u>300,588</u>	
NET CURRENT LIABILITIES			<u>(74,531)</u>		<u>(8,787)</u>
TOTAL ASSETS LESS CURRENT LIABILITIES			<u>(69,366)</u>		<u>(1,930)</u>
CAPITAL AND RESERVES					
Called up share capital	7		100		1
Retained earnings	8		<u>(69,466)</u>		<u>(1,931)</u>
SHAREHOLDERS' FUNDS			<u>(69,366)</u>		<u>(1,930)</u>

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2025 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:

- ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 9 June 2026 and were signed by:

E Singh Chuhan - Director

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025**

1. STATUTORY INFORMATION

A-Tek Pharma LTD is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Going Concern

The accounts have been prepared on a going concern basis. The losses generated in the accounts are currently being funded by the Director.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery - 20% on reducing balance

Computer equipment - 33% on cost

Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments

Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2025

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 4 (2024 - 5) .

4. TANGIBLE FIXED ASSETS

	Plant and machinery etc £
COST	
At 1 January 2025 and 31 December 2025	<u>11,322</u>
DEPRECIATION	
At 1 January 2025	4,465
Charge for year	<u>1,692</u>
At 31 December 2025	<u>6,157</u>
NET BOOK VALUE	
At 31 December 2025	<u>5,165</u>
At 31 December 2024	<u>6,857</u>

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	31/12/25 £	31/12/24 £
Trade debtors	506	37,750
Other debtors	<u>259</u>	<u>296</u>
	<u>765</u>	<u>38,046</u>

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	31/12/25 £	31/12/24 £
Bank loans and overdrafts	4,627	-
Trade creditors	-	25,778
Taxation and social security	83,522	8,392
Other creditors	<u>230,903</u>	<u>266,418</u>
	<u>319,052</u>	<u>300,588</u>

7. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:				
Number:	Class:	Nominal value:	31/12/25	31/12/24
			£	£
100	Ordinary	£1	<u>100</u>	<u>1</u>

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2025

8. RESERVES

	Retained earnings £
At 1 January 2025	(1,931)
Deficit for the year	<u>(67,535)</u>
At 31 December 2025	<u>(69,466)</u>

9. DIRECTOR'S ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to a director subsisted during the years ended 31 December 2025 and 31 December 2024:

	31/12/25 £	31/12/24 £
E Singh Chuhan		
Balance outstanding at start of year	(252,419)	(171,408)
Amounts advanced	43,359	-
Amounts repaid	(16,698)	(81,011)
Amounts written off	-	-
Amounts waived	-	-
Balance outstanding at end of year	<u>(225,758)</u>	<u>(252,419)</u>

10. ULTIMATE CONTROLLING PARTY

The ultimate controlling party is E Singh Chuhan.

**CHARTERED CERTIFIED ACCOUNTANTS' REPORT TO THE DIRECTOR
ON THE UNAUDITED FINANCIAL STATEMENTS OF
A-TEK PHARMA LTD**

The following reproduces the text of the report prepared for the director in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Balance Sheet. Readers are cautioned that the Income Statement and certain other primary statements and the Report of the Director are not required to be filed with the Registrar of Companies.

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of A-Tek Pharma LTD for the year ended 31 December 2025 which comprise the Income Statement, Other Comprehensive Income, Balance Sheet, Statement of Changes in Equity and the related notes from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Association of Chartered Certified Accountants, we are subject to its ethical and other professional requirements which are detailed at accaglobal.com/rulebook.

This report is made solely to the director of A-Tek Pharma LTD in accordance with our terms of engagement. Our work has been undertaken solely to prepare for your approval the financial statements of A-Tek Pharma LTD and state those matters that we have agreed to state to the director of A-Tek Pharma LTD in this report in accordance with the requirements of the Association of Chartered Certified Accountants as detailed at <https://www.accaglobal.com/gb/en/technical-activities/technical-resources-search/2009/october/factsheet-163-audit-exempt-companies.html>.

To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and its director for our work or for this report.

It is your duty to ensure that A-Tek Pharma LTD has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and loss of A-Tek Pharma LTD. You consider that A-Tek Pharma LTD is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of A-Tek Pharma LTD. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

MDH
Chartered Certified Accountants
21 Stafford Road
Croydon
Surrey
CR0 4NG

9 June 2026

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.